A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers

• Status: Not yet recruiting
• Trial end date: 2020-07-31
• Target enrollment: 0
• Participant gender: All

Summary

A multicenter randomized clinical trial aiming to assess the efficacy of hydroxychloroquine associated to Zinc compared to hydroxychloroquine, in the prevention of Military Health Professionals Exposed to SARS CoV2 in Tunisia

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Military Hospital of Tunis
• Collaborators: Dacima Consulting; UR17DN02 : Autoimmune Diseases Research Unit
• Treatments: Hydroxychloroquine; Zinc

Criteria

Inclusion Criteria:

• No self-medication with chloroquine, hydroxychloroquine or antivirals

• COVID-19 negative diagnosis confirmed by "rapid test" and "PCR test" (Polymerase Chain Reaction test)

• No clinical symptoms suggestive of COVID-19

• Having given written consent for their participation in the study

Exclusion Criteria:

• Participation in other clinical trials for the treatment or prevention of SARS-COV-2 infection within 30 days before inclusion

• Hypersensitivity to any of the drugs or to any of its excipients.

• ECG showing rhythm disturbances, QT interval> 500 ms, conduction disturbances.

• Severe hepatic impairment.

• Concomitant treatments : colchicin, ergot of rye, pimozide, mizolastin, simvastatin, lomitapide, alfuzosin, dapoxetin, avanafil, ivabradin, eplerenone, dronedaron, quetiapine, ticagrelor, cisapride, astemizole, astemizol.

• Retinal pathology.

• Epilepsy.

• Myasthenia.

• Psoriasis.

• Methemoglobinemia.

• Porphyria.

• Pregnant or lactating women

• Contraindication to the study products